FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023981696> ?p ?o ?g. }

• W2023981696 abstract "You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness1 Apr 201171 THE COST-EFFECTIVENESS OF THE DOUBLE BENEFIT OF 5-ALPHA-REDUCTASE INHIBITOR (5ARI) CHEMOPREVENTION ON BOTH UNDISCLOSED GENITOURINARY SYMPTOMS AND PROSTATE CANCER Stacy Westerman, Steven Zeliadt, John Gore, and Daniel Lin Stacy WestermanStacy Westerman Seattle, WA More articles by this author , Steven ZeliadtSteven Zeliadt Seattle, WA More articles by this author , John GoreJohn Gore Seattle, WA More articles by this author , and Daniel LinDaniel Lin Seattle, WA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.135AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Use of 5-alpha-reductase inhibitors (5ARI) may have benefit for the prevention of prostate cancer, as well as in the reduction in symptoms of undisclosed genitourinary symptoms never brought to clinical attention. We sought to evaluate the cost effectiveness of chemoprevention with 5ARIs on men over age 50 treated in the Veteran Affairs Healthcare System. METHODS We developed a Markov model with health states for prostate cancer, undisclosed benign prostatic hypertrophy (BPH), and clinically managed BPH beginning at age 50. Age-specific incidence rates of undisclosed and managed BPH were obtained from the literature. The reduction of prostate cancer incidence and BPH-related events on 5ARIs were derived from randomized controlled clinical trials. Men with undisclosed BPH were assigned a utility of 0.93, a 0.04 decline from 0.97 if symptoms were avoided with chemoprevention. We included costs of initial treatment and continuing care for prostate cancer, medical treatment for BPH, clinical BPH events including acute urinary retention and transurethral resection of the prostate, and the annual cost of 5ARI chemoprevention. We conducted sensitivity analyses that varied the cost of 5ARIs from $144/yr based on the Federal supply schedule (FSS) to $521/yr based on the average wholesale price (AWP). RESULTS Without 5ARI chemoprevention, 20.4% of men in our model would be diagnosed with prostate cancer over their lifetime with 3.0% prostate cancer-specific mortality. On 5ARIs, incidence and mortality decreased to 16.5% and 2.5%, respectively. At age 70, our model predicted a 28.5% prevalence of undisclosed BPH without chemoprevention, which would be reduced by half with 5ARI chemoprevention. Our model was sensitive to drug price: the incremental cost-effectiveness ratio ranged from $28,170/quality-adjusted life year (QALY) based on FSS cost, to $88,090/QALY based on AWP. CONCLUSIONS Based on conservative assumptions, 5ARI chemoprevention is cost-effective, particularly in the context of negotiated Federal drug prices. Broader use of chemoprevention with 5ARI could greatly reduce the burden of undisclosed genitourinary symptoms among men in the VA in addition to reducing prostate cancer incidence. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e31 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Stacy Westerman Seattle, WA More articles by this author Steven Zeliadt Seattle, WA More articles by this author John Gore Seattle, WA More articles by this author Daniel Lin Seattle, WA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2023981696 created "2016-06-24" @default.
• W2023981696 creator A5003319562 @default.
• W2023981696 creator A5013194294 @default.
• W2023981696 creator A5054777610 @default.
• W2023981696 creator A5071006955 @default.
• W2023981696 date "2011-04-01" @default.
• W2023981696 modified "2023-09-27" @default.
• W2023981696 title "71 THE COST-EFFECTIVENESS OF THE DOUBLE BENEFIT OF 5-ALPHA-REDUCTASE INHIBITOR (5ARI) CHEMOPREVENTION ON BOTH UNDISCLOSED GENITOURINARY SYMPTOMS AND PROSTATE CANCER" @default.
• W2023981696 doi "https://doi.org/10.1016/j.juro.2011.02.135" @default.
• W2023981696 hasPublicationYear "2011" @default.
• W2023981696 type Work @default.
• W2023981696 sameAs 2023981696 @default.
• W2023981696 citedByCount "0" @default.
• W2023981696 crossrefType "journal-article" @default.
• W2023981696 hasAuthorship W2023981696A5003319562 @default.
• W2023981696 hasAuthorship W2023981696A5013194294 @default.
• W2023981696 hasAuthorship W2023981696A5054777610 @default.
• W2023981696 hasAuthorship W2023981696A5071006955 @default.
• W2023981696 hasConcept C120665830 @default.
• W2023981696 hasConcept C121332964 @default.
• W2023981696 hasConcept C121608353 @default.
• W2023981696 hasConcept C126322002 @default.
• W2023981696 hasConcept C126894567 @default.
• W2023981696 hasConcept C133507102 @default.
• W2023981696 hasConcept C160735492 @default.
• W2023981696 hasConcept C162324750 @default.
• W2023981696 hasConcept C2775874879 @default.
• W2023981696 hasConcept C2776235491 @default.
• W2023981696 hasConcept C2778878792 @default.
• W2023981696 hasConcept C2780192828 @default.
• W2023981696 hasConcept C2910366748 @default.
• W2023981696 hasConcept C29456083 @default.
• W2023981696 hasConcept C50522688 @default.
• W2023981696 hasConcept C512399662 @default.
• W2023981696 hasConcept C535046627 @default.
• W2023981696 hasConcept C61511704 @default.
• W2023981696 hasConcept C71924100 @default.
• W2023981696 hasConceptScore W2023981696C120665830 @default.
• W2023981696 hasConceptScore W2023981696C121332964 @default.
• W2023981696 hasConceptScore W2023981696C121608353 @default.
• W2023981696 hasConceptScore W2023981696C126322002 @default.
• W2023981696 hasConceptScore W2023981696C126894567 @default.
• W2023981696 hasConceptScore W2023981696C133507102 @default.
• W2023981696 hasConceptScore W2023981696C160735492 @default.
• W2023981696 hasConceptScore W2023981696C162324750 @default.
• W2023981696 hasConceptScore W2023981696C2775874879 @default.
• W2023981696 hasConceptScore W2023981696C2776235491 @default.
• W2023981696 hasConceptScore W2023981696C2778878792 @default.
• W2023981696 hasConceptScore W2023981696C2780192828 @default.
• W2023981696 hasConceptScore W2023981696C2910366748 @default.
• W2023981696 hasConceptScore W2023981696C29456083 @default.
• W2023981696 hasConceptScore W2023981696C50522688 @default.
• W2023981696 hasConceptScore W2023981696C512399662 @default.
• W2023981696 hasConceptScore W2023981696C535046627 @default.
• W2023981696 hasConceptScore W2023981696C61511704 @default.
• W2023981696 hasConceptScore W2023981696C71924100 @default.
• W2023981696 hasIssue "4S" @default.
• W2023981696 hasLocation W20239816961 @default.
• W2023981696 hasOpenAccess W2023981696 @default.
• W2023981696 hasPrimaryLocation W20239816961 @default.
• W2023981696 hasRelatedWork W1979522210 @default.
• W2023981696 hasRelatedWork W1980309257 @default.
• W2023981696 hasRelatedWork W1997350508 @default.
• W2023981696 hasRelatedWork W2105243838 @default.
• W2023981696 hasRelatedWork W2110860120 @default.
• W2023981696 hasRelatedWork W2151547940 @default.
• W2023981696 hasRelatedWork W2159992888 @default.
• W2023981696 hasRelatedWork W2223219573 @default.
• W2023981696 hasRelatedWork W2417549345 @default.
• W2023981696 hasRelatedWork W3163649103 @default.
• W2023981696 hasVolume "185" @default.
• W2023981696 isParatext "false" @default.
• W2023981696 isRetracted "false" @default.
• W2023981696 magId "2023981696" @default.
• W2023981696 workType "article" @default.